Patents Issued in March 20, 2018
-
Patent number: 9920100Abstract: The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin Met e 1. Also provided are compositions and methods of use thereof to reduce, minimize or eliminate an allergic response to arthropods and/or shellfish.Type: GrantFiled: June 3, 2016Date of Patent: March 20, 2018Assignees: The Chinese University of Hong Kong, The Regents of the University of CaliforniaInventors: Patrick Leung, Ka Hou Chu, Yee Yan Wai, Yat Hin Nicki Leung
-
Patent number: 9920101Abstract: The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.Type: GrantFiled: March 27, 2015Date of Patent: March 20, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Horst Rose, Dania Birte Reiche, Harald Tammen
-
Patent number: 9920102Abstract: Fluorescent and non-fluorescent fusion tags derived from green fluorescent protein (GFP). The fusion tags harbor substitutions with respect to GFP that increase expression of target proteins to which the fusion tags are fused; increase solubility; prevent dimerization and oligomerization, particularly in oxidizing environments such as the endoplasmic reticulum (ER); and, in some cases, enhance fluorescence of the fusion tag itself. The substitutions include various combinations of substitutions at select cysteine residues in GFP, substitutions in or near the GFP chromophore, and/or other substitutions. The fusion tags can be used for increasing expression of target proteins for mass production thereof or as a fluorescent tag.Type: GrantFiled: May 12, 2016Date of Patent: March 20, 2018Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventors: Erik Lee Snapp, Lindsey M. Costantini
-
Patent number: 9920103Abstract: The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock.Type: GrantFiled: April 6, 2011Date of Patent: March 20, 2018Assignees: BIOPROTEIN TECHNOLOGIES SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Pierre-Jean Ripoll, Laurent Lagrost
-
Patent number: 9920104Abstract: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.Type: GrantFiled: September 25, 2014Date of Patent: March 20, 2018Assignee: UT-Battelle, LLCInventor: Cymbeline T. Culiat
-
Patent number: 9920105Abstract: A fusion polypeptide, including a first polypeptide fragment including 5 to 30 amino acids, the first polypetide fragment is fused between a first amino acid and a fifth amino acid of a fourth loop of a human-derived ferritin monomer.Type: GrantFiled: August 7, 2015Date of Patent: March 20, 2018Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Eunsung Jun, Jaeog Jeon, Soyoun Kim, In-Seop So, In-San Kim, Sun-Ji Kim
-
Patent number: 9920106Abstract: Novel GLP-1 compounds and their therapeutic use.Type: GrantFiled: May 16, 2012Date of Patent: March 20, 2018Assignee: Novo Nordisk A/SInventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
-
Patent number: 9920107Abstract: The present invention refers to a method of purification of HMG (human menopausal gonadotropin) by multimodal chromatography in order to obtain HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition.Type: GrantFiled: May 21, 2015Date of Patent: March 20, 2018Assignees: INSTITUTO MASSONE S.A., RAUL ENRIQUE MASSONEInventors: Liliana Balanián, Mariana Cancela, Claudio Wolfenson, José Groisman
-
Patent number: 9920108Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: November 30, 2015Date of Patent: March 20, 2018Assignee: BRISTOl-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
-
Patent number: 9920109Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing and purifying such molecules.Type: GrantFiled: August 19, 2013Date of Patent: March 20, 2018Assignee: Inhibrx LPInventors: Brendan Eckelman, John Timmer, Quinn Deveraux
-
Patent number: 9920110Abstract: In some embodiments, the invention relates to methods for creating a monoclonal antibody that specifically binds to antigen. The method may start from a polyclonal population of antibodies such as a non-specific polyclonal population or a polyclonal population of antibodies that specifically bind to the antigen. The method includes obtaining nucleic acid molecules encoding heavy and light immunoglobulin chains (or variable regions thereof) of multiple immunoglobulins from an animal; obtaining mass spectra information of peptide fragments of a population of polyclonal immunoglobulins that specifically bind to an antigen of choice; comparing and/or correlating the mass spectra information of the peptide fragments of the polyclonal immunoglobulins with predicted mass spectra information of predicted amino acid sequences encoded by the nucleic acid molecules, and then assembling the heavy and light chains to create an antibody (or variable region thereof) that specifically binds to the antigen.Type: GrantFiled: March 9, 2012Date of Patent: March 20, 2018Assignee: Cell Signaling Technology, Inc.Inventors: Roberto Polakiewicz, Wan Cheung Cheung, John Edward Rush, II, Sean Andre Beausoleil
-
Patent number: 9920111Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: April 21, 2015Date of Patent: March 20, 2018Assignees: Theraclone Sciences, Inc., International Aids Vaccine Initiative, The Scripps Research InstituteInventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Patent number: 9920112Abstract: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.Type: GrantFiled: October 23, 2013Date of Patent: March 20, 2018Assignee: EMD Millipore CorporationInventor: Shari Spector
-
Patent number: 9920113Abstract: Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as Candida species and/or Staphylococcus species.Type: GrantFiled: May 26, 2016Date of Patent: March 20, 2018Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI, YALE UNIVERSITYInventors: Margaret K. Hostetter, Long Lu, Julianne Vernadette Green, Alexey Porollo, Kris I. Orsborn, Khoon Ghee Queenie Tan, Kenneth Greis, David Andes
-
Patent number: 9920114Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.Type: GrantFiled: March 16, 2017Date of Patent: March 20, 2018Assignee: AMGEN INC.Inventors: Bruce D. Mason, Jifeng Zhang, Richard L. Remmele, Jr.
-
Patent number: 9920115Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.Type: GrantFiled: September 14, 2017Date of Patent: March 20, 2018Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
-
Patent number: 9920116Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: September 22, 2017Date of Patent: March 20, 2018Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 9920117Abstract: Two types of antibodies (35-1 antibody and 292 antibody) capable of binding to phenylalanine at position 115, isoleucine at position 117, glycine at position 140, glutamic acid at position 141, and arginine at position 142 of a human HB-EGF protein were successfully obtained. Then, it was also found that these antibodies had an activity of suppressing cleavage of the human HB-EGF protein, and an activity of suppressing EGFR phosphorylation that would occur when the human HB-EGF bound to the EGFR. Further, determined were amino acid sequences of light chain and heavy chain variable regions of these antibodies and sequences of CDRs of each of the variable regions.Type: GrantFiled: April 17, 2014Date of Patent: March 20, 2018Assignee: MEDICAL & BIOLOGICAL LABORATIVES CO., LTD.Inventors: Kenichiro Ono, Junichi Akatsuka
-
Patent number: 9920118Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: GrantFiled: October 29, 2015Date of Patent: March 20, 2018Assignee: NGM Biopharmaceuticals, Inc.Inventors: Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
-
Patent number: 9920119Abstract: New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.Type: GrantFiled: October 26, 2012Date of Patent: March 20, 2018Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean-Luc Taupin, Sophie Daburon, Jean-Francois Moreau, Myriam Capone
-
Patent number: 9920120Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.Type: GrantFiled: March 9, 2016Date of Patent: March 20, 2018Assignee: Genentech, Inc.Inventors: X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
-
Patent number: 9920121Abstract: The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.Type: GrantFiled: January 27, 2014Date of Patent: March 20, 2018Assignee: AMGEN INC.Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan
-
Patent number: 9920122Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: May 3, 2016Date of Patent: March 20, 2018Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars van den Berg
-
Patent number: 9920123Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.Type: GrantFiled: October 26, 2016Date of Patent: March 20, 2018Assignee: Genentech, Inc.Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
-
Patent number: 9920124Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.Type: GrantFiled: December 19, 2013Date of Patent: March 20, 2018Assignee: MedImmune, LLCInventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
-
Patent number: 9920125Abstract: Methods for reduction of aggregate levels in antibody and other protein preparations comprising the steps of treatment with an organic multivalent cation (e.g., ethacridine, chlorhexidine, or polyethylenimine) and treatment with a composition having a combination of surfaces bearing electronegative chemical moieties and surfaces bearing electropositive chemical moieties.Type: GrantFiled: November 26, 2014Date of Patent: March 20, 2018Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Peter Gagnon
-
Patent number: 9920127Abstract: Disclosed herein are methods of treating pain using RANK/RANKL antagonists.Type: GrantFiled: June 9, 2017Date of Patent: March 20, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9920128Abstract: A method for synthesizing an antiserum for rapid-turnaround therapies includes collecting antibody-secreting cells from a test subject, wherein the test subject has been exposed to a target biological agent and has produced an antibody response; selecting a subset of the antibody-secreting cells, the subset of the antibody-secreting cells producing antibodies that neutralize the target biological agent; generating variable-region-coding DNA sequences from the antibodies that neutralize the target biological agent; tagging amplicons of the variable-region-coding DNA sequences with unique nucleic acid identifiers to associate the variable-region-coding DNA sequences derived from individual ones of the subset of the antibody-secreting cells; analyzing antibody-type distribution in a natural immune response; synthesizing antibodies from the variable-region-coding DNA sequences to form synthetic antibodies; and mixing the synthetic antibodies in a proportion equal to the antibody-type distribution in the natural iType: GrantFiled: January 20, 2016Date of Patent: March 20, 2018Assignee: The Johns Hopkins UniversityInventors: Jeffrey S. Lin, Andrew B. Feldman, Jared D. Evans, Joshua T. Wolfe, David Weitz, John Heyman, Andrew S. Pekosz
-
Patent number: 9920129Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: GrantFiled: April 29, 2016Date of Patent: March 20, 2018Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIY AKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
-
Patent number: 9920130Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.Type: GrantFiled: November 26, 2013Date of Patent: March 20, 2018Assignee: KATINGER GMBHInventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
-
Patent number: 9920131Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.Type: GrantFiled: December 21, 2016Date of Patent: March 20, 2018Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Jeffrey David Kearns, Beni B. Wolf
-
Patent number: 9920132Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.Type: GrantFiled: May 19, 2017Date of Patent: March 20, 2018Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK Blutspendedienst Baden-Wurttemberg-Hessen gGmbHInventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
-
Patent number: 9920133Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.Type: GrantFiled: February 3, 2015Date of Patent: March 20, 2018Assignees: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Yoshikatsu Koga, Yoshiyuki Yamamoto, Ryuta Sato, Ryo Tsumura, Kazunori Kataoka, Nobuhiro Nishiyama, Yutaka Miura, Shino Manabe, Yasuki Kato
-
Patent number: 9920134Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: GrantFiled: June 30, 2011Date of Patent: March 20, 2018Assignee: AMGEN INC.Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terrence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
-
Patent number: 9920135Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.Type: GrantFiled: July 30, 2014Date of Patent: March 20, 2018Assignee: JUNTENDO EDUCATIONAL FOUNDATIONInventors: Chikao Morimoto, Ryo Hatano, Taketo Yamada, Kei Ohnuma
-
Patent number: 9920136Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.Type: GrantFiled: February 10, 2014Date of Patent: March 20, 2018Assignee: ARK Diagnostics, Inc.Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
-
Patent number: 9920137Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.Type: GrantFiled: July 5, 2015Date of Patent: March 20, 2018Assignee: LIPOXEN TECHNOLOGIES LIMITEDInventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
-
Patent number: 9920138Abstract: The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.Type: GrantFiled: October 16, 2009Date of Patent: March 20, 2018Assignee: Bayer Intellectual Property GMBHInventors: Claus Frohberg, Waltraud Vorwerg, Sylvia Radosta
-
Patent number: 9920139Abstract: Provided is a suspension comprising liquid droplets dispersed in an aqueous medium, wherein said droplets comprise (a) one or more water-insoluble compounds, and (b) a vinyl polyelectrolyte (PED) having a polarity, and wherein said aqueous medium comprises a polyelectrolyte (PEW) having a polarity that is opposite to the polarity of said polyelectrolyte (PED). Also provided are a method of making such a suspension and a method using such a suspension in a process of suspension polymerization.Type: GrantFiled: December 15, 2015Date of Patent: March 20, 2018Assignees: Rohm and Haas Company, Dow Global Technologies LLCInventors: Matthew D. Reichert, Alfred K. Schultz, Andrew M. Savo, Steven Rosenberg, Ralph C. Even, Lester H. Mcintosh, III, Robert Johnson, John David Finch, Decai Yu
-
Patent number: 9920140Abstract: The invention relates to aqueous, cationically stabilized primary dispersions comprising dispersed polymer particles having a Z-average particle diameter of 5 to 500 nm and which are obtainable by emulsion polymerization of at least one olefinically unsaturated monomer (A). The emulsion polymerization takes place in the presence of one or more emulsifiers (EQ) having the following general formula: R1—N?(R2)(R3)(R4)X?, where R1 is a moiety with 15 to 40 carbon atoms which contains at least one aromatic group and at least one aliphatic group, and which contains at least one functional group selected from hydroxyl groups, thiol groups, and primary or secondary amino groups, and/or has at least one carbon-carbon multiple bond, R2, R3, and R4, independently of one another, are the same or different aliphatic moieties containing 1 to 14 carbon atoms, and X stands for the acid anion of an organic or inorganic acid.Type: GrantFiled: December 20, 2013Date of Patent: March 20, 2018Inventors: Konstantinos Markou, Andreas Niegemeier, Sabine Holtschulte
-
Patent number: 9920141Abstract: A process for manufacturing a dispersions of a vinylidene fluoride (VDF) thermoplastic polymer [polymer (F)], said process comprising polymerizing VDF in an aqueous phase comprising: at least one surfactant selected from the group consisting of non-fluorinated surfactants [surfactant (HS)] and fluorinated surfactants having a molecular weight of less than 400 [surfactant (FS)]; and at least one functional (per)fluoropolyether (functional PFPE) comprising at least one (per)fluoropolyoxyalkylene chain [chain (R?F)] and at least one functional group, said functional PFPE having a number average molecular weight of at least 1000 and a solubility in water of less than 1% by weight at 25° C., wherein said functional PFPE is present in the aqueous phase in an amount of 0.001 to 0.3 g/l.Type: GrantFiled: December 15, 2010Date of Patent: March 20, 2018Assignee: SOLVAY SPECIALTY POLYMERS ITALY S.P.A.Inventors: Fabrizio Spada, Bradley Lane Kent
-
Patent number: 9920142Abstract: A (meth)acrylic resin composition is obtained by a method that comprises: preparing a liquid starting material (A) comprising methyl methacrylate, an acrylic acid alkyl ester and a chain transfer agent, having a mass ratio of the acrylic acid alkyl ester to the methyl methacrylate of 0/100 to 20/80, and having a dissolved oxygen concentration of not more than 50 ppm, preparing a liquid starting material (B) comprising a radical polymerization initiator, a polymerization inhibitor and methyl methacrylate, and having been maintained at a temperature of not more than 10° C. in the presence of oxygen, continuously feeding the liquid starting material (A) and the liquid starting material (B) into a tank reactor, allowing bulk polymerization to proceed in the tank reactor at a polymerization conversion ratio of 40 to 70% by mass to give a reaction product, and continuously discharging the reaction product from the tank reactor.Type: GrantFiled: February 6, 2015Date of Patent: March 20, 2018Assignee: KURARAY CO., LTD.Inventors: Yasuhito Kitade, Hiroshi Ozawa, Shouji Tanaka
-
Patent number: 9920143Abstract: A fluorine-containing highly branched polymer obtained by polymerizing a polyfunctional monomer A that has two or more radically polymerizable double bonds and all or a portion of which has a bisphenol structure, a monomer B having a fluoroalkyl group and at least one radically polymerizable double bond, within a molecule, and a monomer C having at least one ring-opening polymerizable group selected from the group including an epoxy group and an oxetanyl group, and having at least one radically polymerizable double bond, within a molecule, under the presence of a polymerization initiator D with an amount of 5% by mole to 200% by mole to the number of moles of the polyfunctional monomer A; an epoxy resin composition including the polymer; and an epoxy resin cured product obtained from the resin composition.Type: GrantFiled: June 6, 2013Date of Patent: March 20, 2018Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Tomoko Misaki, Motonobu Matsuyama, Masayuki Haraguchi, Masaaki Ozawa
-
Patent number: 9920144Abstract: The present disclosure relates to a porous solid adduct comprising magnesium chloride and ethanol, characterized by a relationship between the content of alcohol, average pore radius and amount of porosity deriving from pores with radii of 100-1000 nm, and catalyst components produced therefrom that are capable of producing polyolefins with increased porosity.Type: GrantFiled: August 20, 2015Date of Patent: March 20, 2018Assignee: Basell Poliolefine Italia S.r.l.Inventors: Arrigo Arletti, Lucia Caiazzo, Gianni Collina, Daniele Evangelisti, Ofelia Fusco, Benedetta Gaddi
-
Patent number: 9920145Abstract: The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C5-C10)cycloalkyl and (C2-C10)heterocyclyl. Fused ring A is substituted with (R1)1-8 and fused ring B is substituted with —(OC(O)R?C(O)R2)1-8. At each occurrence R? is independently chosen from (C2-C10)alkanylene, (C2-C10)alkenylene, (C2-C10)alkynylene, C5-C20(arylene), and (C1-C20)heteroarylene, wherein R? is unsubstituted or substituted. At each occurrence R1 is independently selected from —OH, —OR3, and —OC(O)R?C(O)R2. At each occurrence R2 is independently chosen from —OH, —OR3, —NH2, —NHR3, and —NR32. At each occurrence R3 is independently chosen from (C1-C10)alkanyl, (C2-C10)alkenyl, (C2-C10)alkynyl, C5-C20(aryl), and (C1-C20)heteroaryl, wherein R3 is unsubstituted or substituted.Type: GrantFiled: April 28, 2017Date of Patent: March 20, 2018Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Jason Shih-Hao Chen, Michael Richard Kessler, Michael Dennis Zenner
-
Patent number: 9920146Abstract: Provided is a method of treatment of an alcoholic beverage, particularly beer or wine, for removing ingredient(s) causing undesirable sulfury and/or fatty flavor(s), by contacting the beverage with a composition having a polymer-hydrogen peroxide complex, wherein the polymer is derived from at least one N-vinyl lactam monomer, and wherein the hydrogen peroxide is present in an amount from about 1% by weight to about 50% by weight of the complex. Provided further is a method of treatment of an alcoholic beverage to remove at least (a) at least one ingredient causing at least one undesirable sulfury and/or fatty flavor, and (b) at least one ingredient causing colloidal haze, including contacting the beverage with a composition described herein. Provided furthermore is an alcoholic beverage obtained by the method(s) of treatment described herein.Type: GrantFiled: May 21, 2015Date of Patent: March 20, 2018Assignee: ISP Investments LLCInventors: Krishnamurthy Nacharaju, Giovanni Nicola Onnembo, Mustafa Rehmanji, Andrew Mola, Bala Balasanmugam, Joycelyn Yapchulay
-
Patent number: 9920147Abstract: The present technology relates to a polymeric material including a plurality of polymer subunits and an active cross-linker, wherein the active cross-linker is covalently linked to the plurality of polymer subunits. The active cross-linker offers a key building block for constructing novel molecular architecture in chemomechanical soft materials and illustrates a new approach to tailor material properties.Type: GrantFiled: September 8, 2014Date of Patent: March 20, 2018Assignee: Brandeis UniversityInventors: Ye Zhang, Bing Xu
-
Patent number: 9920148Abstract: A vehicle part cover including a methacrylic-based resin (I) having a weight average molecular weight measured by gel permeation chromatography (GPC) of 65,000 to 300,000, the methacrylic-based resin (I) comprising: 50 to 97% by mass of a methacrylate monomer unit (A); 3 to 30% by mass of a structural unit (B) having a ring structure in its main chain, and being at least one selected from the group consisting of a maleimide-based structural unit, a glutaric anhydride structural unit, a glutarimide-based structural unit, and a lactone ring structural unit; and 0 to 20% by mass of another vinyl monomer unit (C) that is copolymerizable with a methacrylate monomer.Type: GrantFiled: October 19, 2012Date of Patent: March 20, 2018Assignee: Asahi Kasei Chemicals CorporationInventor: Fumiki Murakami
-
Patent number: 9920149Abstract: Polymers are functionalized at chain ends thereof with silane-containing carboxyl groups of the formula (I) where R1 and R2 are the same or different and are each an H, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkaryl, alkaryloxy, aralkyl or aralkoxy radical; R3 and R4 are the same or different and are each an H, alkyl, cycloalkyl, aryl, alkaryl or aralkyl radical; and A is a divalent organic radical.Type: GrantFiled: April 11, 2014Date of Patent: March 20, 2018Assignee: ARLANXEO Deutschland GmbHInventors: Norbert Steinhauser, Thomas Gross
-
Patent number: 9920150Abstract: A process is described for the production of phosphorus-containing organic polymers through reaction of dialkyl phosphites with organic polymers comprising carbon-carbon double bonds in the presence of organic compounds that form free radicals under the reaction conditions, with covalent linkage of the phosphorus atom of the dialkyl phosphite to a carbon atom of the organic polymer.Type: GrantFiled: June 6, 2014Date of Patent: March 20, 2018Assignee: BASF SEInventors: Alexander Koenig, Konrad Knoll